Connect with us

News

UK medical cannabis clinic rated ‘Good’ by regulators

This was the first inspection of a cannabis clinic by the Care Quality Commission (CQC).

Published

on

The clinic is said to care for more than 60 percent of all medical cannabis patients in the UK

One of the UK’s leading medical cannabis clinics has been praised by regulators for its efforts to provide safe and effective care.

The Medical Cannabis Clinics (TMCC) has been awarded the first rated ‘Good’ cannabis clinic in the UK by health and social care regulator Care Quality Commission (CQC).

The Lyphe Group-owned clinic, which is said to care for more than 60 percent of all medical cannabis patients in the UK, has passed with a rating of ‘Good’ following a recent inspection by the CQC.

This was the first inspection of a cannabis clinic by the CQC, which regulates to ensure patients are provided with safe, effective, compassionate, and high-quality care. 

The Medical Cannabis Clinics (TMCC) was awarded one of four licences to trade as a cannabis clinic by CQC in 2019, and provides treatment to patients across a number of medical areas including pain and psychiatry. 

The clinic’s first CQC inspection was carried out in response to ‘concerns’ identified by the regulator in a compliance review last year. The report concluded that “improvements have been made”.

The report praised TMCC’s “clear vision” to provide a safe, personalised and high quality service. Care and treatment was said to be delivered according to evidence- based guidelines and feedback from patients was positive.

Regulators also noted a “commitment and appetite to work with external partners to share learning and make the service as accessible as possible”.

Over half of all doctors in the UK that are currently prescribing medical cannabis, are said to be working at TMCC, which operates via telemedicine services. 

Due to growing patient numbers, the clinic is recruiting up to five new doctors each month. 

Chief medical officer, Dr Sunny Nayee said of the CQC rating: “We are delighted to receive this rating from CQC, as it shows that the hard work from the doctors and support staff has all been worth it. The industry is not by any means mature yet and we are always looking for ways to improve how we do things for the greater good of the patient.

“For us, patient safety and efficacious treatment is the central pillar of the clinic, and I am proud this has been noticed by CQC.”

LYPHE Group managing director, Jonathan Nadler, added: “I would like to congratulate everyone at TMCC for playing their part in making the clinic a critical care operator for patients seeking medical cannabis. We have set the standard for all other cannabis clinics to now follow.”

Sarah Sinclair is a respected cannabis journalist writing on subjects related to science, medicine, research, health and wellness. She is managing editor of Cannabis Health, the UK’s leading title covering medical cannabis and CBD, and sister title and Psychedelic Health. Sarah has an NCTJ journalism qualification and an MA in Journalism from the University of Sunderland. Sarah has over six years experience working on newspapers, magazines and digital-first titles, the last two of which have been in the cannabis sector. She has also completed training through the Medical Cannabis Clinicians Society securing a certificate in Medical Cannabis Explained. She is a member of PLEA’s (Patient-Led Engagement for Access) advisory board, has hosted several webinars on cannabis and women's health and has moderated at industry events such as Cannabis Europa. Sarah Sinclair is the editor of Cannabis Health. Got a story? Email sarah@prohibitionpartners.com / Follow us on Twitter: @CannabisHNews / Instagram: @cannabishealthmag

Trending

Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2024 PP Intelligence Ltd.